Nov. 25 at 5:01 PM
$NDRA : A New Era in Liver Health 🧬
ENDRA Life Sciences is now leading the charge in a market projected to reach approximately
$66B by 2033, as fatty liver disease remains a widespread, under diagnosed global epidemic. 🌍
TAEUS is designed to turn standard ultrasound machines into fast, accessible tools for measuring liver fat, aiming to deliver MRI like insight in under a minute, at a fraction of the cost.
Why it matters:
• Liver disease affects over a billion people globally
• Current diagnostics are slow, expensive, and limited
• TAEUS brings advanced screening to everyday clinical settings
What’s next:
ENDRA is moving toward key study updates and regulatory steps that could define the next stage of its commercial path.
A simple idea with huge potential: make liver health screening fast, affordable, and everywhere.📈
Communicated Disclaimer: https://stockresearchtoday.com/pioneering-early-diagnosis-in-fatty-liver-disease/
Sector Peers:
$DXCM $TTOO $BFLY $CDNA
